Nasense Labs Private Limited
Nasense Labs Private Limited is a Private Non-govt company company incorporated in 1995 and based in Telangana, India. Nasense Labs Private Limited operates in Chemical substances used in the manufacture of anti-biotic, manufacturing (NIC 24231) with authorized capital of ₹24.00 Cr and paid-up capital of ₹23.57 Cr. For 2023-24, the company reported revenue of ₹115.64 Cr and profit after tax of ₹2.66 Cr. The board has 2 active directors. RegisterKaro's provisional Compliance Health Score for the company is 100/100 (grade A), based on 4 of 9 signals — full scoring is pending extraction of the company's MCA filing history.
NASENSE LABS PRIVATE LIMITED is the legal entity of Nasense Labs.
Quick facts
Directors
2 activeMCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 27 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 23 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 24 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Nasense Labs Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 850138377 | Kotak Mahindra Bank Ltd(Bank) | ₹21.44 Cr | 04 Jul 2020 | Satisfied |
| 798182295 | Axis Bank Ltd(Bank) | ₹14.24 Cr | 19 Sep 2019 | Satisfied |
| 818365213 | State Bank of India(Bank) | ₹3.44 Cr | 04 Jul 2020 | Open |
| 146012306 | State Bank of India(Bank) | ₹18.62 Cr | 27 Jan 2019 | Open |
Charge IDs, lenders & amounts for Nasense Labs Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
MCA| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| 2023-24 | — | ||||
| 2022-23 | — | ||||
| 2021-22 | — | ||||
| 2018-19 | — | ||||
| 2016-17 | — |
Detailed Financials
4 FYs| Line item | 2023-24 | 2022-23 | 2021-22 | 2018-19 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ||||
| Other income | ||||
| Total income | ||||
| Total expenses | ||||
| Profit before tax | ||||
| Profit / (Loss) after tax | ||||
| Balance sheet | ||||
| Equity / Net worth | ||||
| Borrowings | ||||
| Current liabilities | ||||
| Total liabilities | ||||
| Current assets | ||||
| Cash & equivalents | ||||
| Total assets | ||||
| Employees | — | — | — | — |
Cash-flow statement renders when the AOC-4 XBRL Cash Flow context is parsed during the extract phase.
Compounded Annual Growth Rate
| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue2023-24 | +1.0% | +9.0% | — | |
| Profit after Tax2023-24 | +13.0% | -48.0% | — | |
| Net Worth2023-24 | +4.0% | +9.0% | — |
Financial Ratios
| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| 2016-17 | +4.45% | — | +12.34% | +3.39% | — | |||
| 2018-19 | +4.38% | +22.72% | +7.18% | +3.19% | 1.25 | |||
| 2021-22 | -5.33% | -2.80% | -8.62% | -3.57% | 1.41 | |||
| 2022-23 | +1.91% | +6.62% | +3.19% | +1.42% | 1.24 | |||
| 2023-24 | +2.30% | +0.12% | +3.71% | +1.51% | 1.45 |
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 1 | 2,55,55,303 | 63.53% |
| Institutional Investors | 2 | 22,66,624 | 5.64% |
| Public & Others | 49 | 1,24,00,623 | 30.83% |
Promoter, institutional & public holding for Nasense Labs Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
5 peersTop 10 in Chemical substances used in the manufacture of anti-biotic, manufacturing
by healthView all ›Events & timeline
2External data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.